Camp4 Therapeutics(NASDAQ) CAMP

Camp4 Therapeutics Corporation makes medicines for rare genetic diseases. These treatments help people with severe brain and developmental conditions. The company's technology helps the body produce healthy protein levels.

Treating Rare Genetic Disorders

• CMP-002: Injectable medicine candidate designed to treat SYNGAP1, a severe brain disorder; entering early-stage clinical trials in late 2026.
• RAP Platform: Internal technology used to identify and map the RNAs that turn human genes on or off.
• CNS Programs: Research projects focusing on brain and nervous system diseases where increasing protein levels provides benefit.
• Discovery Partnerships: Strategic collaborations with larger firms to expand the use of company technology into new disease areas.

Strategic Moves and Funding

• Launched an initial public offering that closed on Oct. 15, 2024, to support clinical development.
• Entered a research and license agreement with GSK to study gene upregulation in tissues beyond the central nervous system.
• Secured additional funding through a private placement with two closings in September 2025 and Aug. 3, 2026.
• Completed an underwritten offering of common stock in December 2025 to increase capital resources.

Mapping the Human Genome

Camp4 relies on a proprietary platform that maps the regulatory elements controlling every protein-coding gene in the human body. This approach allows the company to rapidly generate new drug candidates for diseases where increasing protein expression provides benefit.

A Look at the Numbers

• Market capitalization was $253.2 million in the second quarter of 2026, up 766.0% year over year.
• Research and collaboration revenue was $3.1 million for the six-month period ended June 30, 2026.
• Net loss reached $51.9 million for the six-month period ended June 30, 2026, compared to $25.0 million for the same period in 2025.
• Cash and cash equivalents totaled $86.4 million as of June 30, 2026.

Bottom Line

Camp4 has evolved from a private research firm into a clinical-stage public company focused on programmable RNA medicines. Its strategy involves advancing internal brain-focused programs while using strategic partnerships to reach other therapeutic areas.